Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates. I continue to see Jazz stock as a valuation ...

Zymeworks (NASDAQ:ZYME) said it has achieved a $14M cash research milestone through its collaboration with GSK (GSK). Under ...

Harbour BioMed's subsidiary inks $395M deal, ORIC plans Phase 3 trials, Idorsia updates on deals, Sanofi backs Enveda, Zymeworks gets GSK milestone, BerGenBio ends study, Ignota raises £5.5M ...

Zymeworks (ZYME) announced achievement of a $14M cash research milestone from GSK (GSK) associated with a clinical milestone. “In April 2016, ...

Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval of Ziihera® (zanidatamab-hrii), a ...

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Zymeworks Inc. (NYSE:ZYME – Get Free Report) has been given a consensus rating of “Moderate Buy” by the seven research firms ...

Zymeworks (ZYME) appointed Oleg Nodelman to its board of directors, effective February 17. Nodelman is the Founder and Managing Director of ...

VANCOUVER, British Columbia, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology ...